Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Drugs in Development, 2021

According to the recently published report 'Tyrosine Protein Kinase JAK1 – Drugs in Development, 2021'; Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 51 molecules. Out of which approximately 50 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

The report 'Tyrosine Protein Kinase JAK1 – Drugs in Development, 2021' outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 12, 11, 13 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Infectious Disease, Central Nervous System, Cardiovascular, Genetic Disorders, Hematological Disorders, Hormonal Disorders, Metabolic Disorders, Ophthalmology and Women's Health which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Psoriasis, Systemic Lupus Erythematosus, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Coronavirus Disease 2019 (COVID-19), Myelofibrosis, Vitiligo, Graft Versus Host Disease (GVHD), Inflammation, Inflammatory Bowel Disease, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Ankylosing Spondylitis (Bekhterev's Disease), Asthma, Diffuse Large B-Cell Lymphoma, Hidradenitis Suppurativa, Multiple Sclerosis, Peripheral T-Cell Lymphomas (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Bronchiolitis Obliterans, Chronic Lymphocytic Leukemia (CLL), Cytokine Release Syndrome (Cytokine Storm), Dermatitis (Eczema), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Psoriatic Arthritis, Sicca Syndrome (Sjogren), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Triple-Negative Breast Cancer (TNBC), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Aicardi-Goutieres Syndrome (AGS), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Hyperplasia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Graves Diseases, Hairy Cell Leukemia, Hemophagocytic Lymphohistiocytosis, Hepatocellular Carcinoma, Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Idiopathic Pulmonary Fibrosis, Juvenile Arthritis, Keratoconjunctivitis Sicca (Dry Eye), Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lipodystrophy (Lipoatrophy), Lupus Erythematosus, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Myeloproliferative Disorders, Myxoid Liposarcoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Oligoarticular Idiopathic Juvenile Arthritis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Prurigo, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Skin Cancer, Solid Tumor, Spondyloarthritis (Spondyloarthropathy), Squamous Cell Carcinoma, Synovial Sarcoma, Systemic Idiopathic Juvenile Arthritis, T-Cell Lymphomas, Takayasu Arteritis, Thrombocythemia Myelofibrosis and Transitional Cell Carcinoma (Urothelial Cell Carcinoma). Global

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

– The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Aclaris Therapeutics Inc

Alexion Pharmaceuticals Inc

Ashvattha Therapeutics LLC

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celon Pharma SA

Concert Pharmaceuticals Inc

Dizal (Jiangsu) Pharmaceutical Co Ltd

Eli Lilly and Co

Galapagos NV

GlaxoSmithKline Plc

Han Wha Pharma Co Ltd

Hangzhou East China Pharmaceutical Group Co Ltd

HK inno.N Corp

Impetis Biosciences Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Carephar Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Simcere Pharmaceutical Co Ltd

Merck & Co Inc

Nippon Shinyaku Co Ltd

Novartis AG

Pfizer Inc

Sareum Holdings Plc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shenzhen Chipscreen Biosciences Co Ltd

Sierra Oncology Inc

Theravance Biopharma Inc

TLL Pharmaceutical LLC

Wuxi Fuxin Pharmaceutical Research and Development Co Ltd

Table of Contents

Table of Contents

Introduction

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Overview

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Development

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Assessment

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Companies Involved in Therapeutics Development

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Drug Profiles

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Indications, 2021 (Contd..2)

Number of Products under Development by Indications, 2021 (Contd..3)

Number of Products under Development by Indications, 2021 (Contd..4)

Number of Products under Development by Indications, 2021 (Contd..5)

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Companies, 2021 (Contd..5)

Products under Development by Companies, 2021 (Contd..6)

Products under Development by Companies, 2021 (Contd..7)

Products under Development by Companies, 2021 (Contd..8)

Products under Development by Companies, 2021 (Contd..9)

Products under Development by Companies, 2021 (Contd..10)

Products under Development by Companies, 2021 (Contd..11)

Products under Development by Companies, 2021 (Contd..12)

Products under Development by Companies, 2021 (Contd..13)

Products under Development by Companies, 2021 (Contd..14)

Products under Development by Companies, 2021 (Contd..15)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by AbbVie Inc, 2021

Pipeline by Aclaris Therapeutics Inc, 2021

Pipeline by Alexion Pharmaceuticals Inc, 2021

Pipeline by Ashvattha Therapeutics LLC, 2021

Pipeline by Astellas Pharma Inc, 2021

Pipeline by AstraZeneca Plc, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by Celon Pharma SA, 2021

Pipeline by Concert Pharmaceuticals Inc, 2021

Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, 2021

Pipeline by Eli Lilly and Co, 2021

Pipeline by Galapagos NV, 2021

Pipeline by GlaxoSmithKline Plc, 2021

Pipeline by Han Wha Pharma Co Ltd, 2021

Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2021

Pipeline by HK inno.N Corp, 2021

Pipeline by Impetis Biosciences Ltd, 2021

Pipeline by Incyte Corp, 2021

Pipeline by Japan Tobacco Inc, 2021

Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Pipeline by Jiangsu Simcere Pharmaceutical Co Ltd, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Nippon Shinyaku Co Ltd, 2021

Pipeline by Novartis AG, 2021

Pipeline by Pfizer Inc, 2021

Pipeline by Sareum Holdings Plc, 2021

Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2021

Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021

Pipeline by Sierra Oncology Inc, 2021

Pipeline by Theravance Biopharma Inc, 2021

Pipeline by TLL Pharmaceutical LLC, 2021

Pipeline by Wuxi Fuxin Pharmaceutical Research and Development Co Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Dormant Products, 2021 (Contd..2)

Dormant Products, 2021 (Contd..3)

Discontinued Products, 2021

Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports